VJHemOnc is committed to improving our service to you

ASH 2019 | DTRM-12 with everolimus and pomalidomide in R/R CLL and B-cell lymphomas

VJHemOnc is committed to improving our service to you

Anthony Mato

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a phase Ia/Ib study (NCT02900716) exploring the synthetic lethality of the orally administered novel BTK inhibitor, dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide (DTRM-555) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) or other B-cell lymphomas. Encouraging clinical activity was observed in several high-risk, multi-refractory CLL and lymphoma patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter